* we discuss what a recently rolled-out GLP-1 pill, the first of its kind approved for obesity, could mean for the future of weight loss.
Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes...
In this episode, Dr. Spencer Nadolsky discusses the transformative role of GLP-1 medications in obesity treatment. He explains the mechanism of GLP-1, its rise in popularity, associated risks, and the importance of personalized medicine. The conversation also touches on the significance of...
* The anticipated lower cash price – reported at approximately $149 – could substantially improve access, particularly compared with injectable GLP-1–based weight loss therapies. The hosts discuss patient preferences, noting that an oral option may appeal to individuals hesitant about injections...
New drug candidates could transform the obesity treatment landscape again, as pill formulations and multi-agonist treatments undergo clinical trials. Endocrine Society experts Priya Jaisinghani, MD, DABOM, and Mehmet Furkan Burak, MD, discussed how emerging treatments could improve obesity...
Figure 1. Comparative overview of therapeutic approaches for male hypogonadism and metabolic dysfunction. The figure summarizes the key advantages and disadvantages of three main management modalities: GLP-1 receptor agonists (GLP-1 RAs), lifestyle modification (diet and exercise), and...
https://www.obesity-abstracts.org/ob/0005/ob0005oc1
Background
Male obesity-related secondary hypogonadism (MOSH) affects two-thirds of men with BMI ≥40 kg/m2 and is associated with increased mortality. Animal models suggest decreased hypothalamic function in obesity-related hypogonadism...
In this episode of On the Edge of Breakthrough, host Dr. Monty Pal sits down with Dr. Charles Brenner, an internationally recognized expert in metabolism and the founding Chair of the Department of Diabetes & Cancer Metabolism at City of Hope. Together, they explore the metabolic links between...
* Among the human studies, 9 evaluated testosterone levels (total and/or free), 6 reported on gonadotropins (LH, FSH), and 5 assessed clinical hypogonadal symptoms such as libido and erectile function. In total, 7 human studies demonstrated a statistically significant increase in testosterone...
In this episode of You Are Not Broken, Dr. Kelly Casperson sits down with endocrinologist and obesity medicine expert Dr. Rocio Salas-Whalen for a deep dive into GLP-1 medications (like Ozempic, Wegovy, and Mounjaro).
They cover everything you should be asking but probably haven’t heard...
GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in...
Ozempic and similar medications have received widespread attention for the treatment of diabetes and weight loss. There’s also growing research that they may help treat heart disease, sleep apnea, kidney disease, substance use disorder and other conditions. Demand has surged for the medications...
* Venesection is not recommended except for clonal erythrocytosis, due to its potential pro-thrombotic effects.
* Repeated venesection can lead to decreased tissue oxygen pressure (pO2) and depletion of iron stores; factors which activate biological pathways that may paradoxically promote the...
* Reference intervals for 216 men aged 45-65 years with a BMI <25 kg/m2 were 8.3 – 28.7 nmol/l for TT, 139 – 422 pmol/l for FT, and 17.7 – 80.8 nmol/l for SHBG. As BMI increases, a greater proportion of men fall below the lower limit of the reference intervals. Specifically, among men with a BMI...
* Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health.
Table 1. Impact of GLP-1 Receptor Agonist Therapy on...
https://www.urologytimes.com/view/pearls-perspectives-urology-role-in-glp-1-ra-treatments-with-hossein-sadeghi-nejad-md-and-nathalie-eid-ba
In this 2-part episode of Pearls and Perspectives from the American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas, NV, host Amy Pearlman...
https://www.cnbc.com/2025/04/25/novo-nordisk-legal-win-bars-many-compounded-wegovy-ozempic-drugs.html
Key Points
Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker’s blockbuster weight...
Everyone is talking about GLP-1s. As these so-called "miracle drugs" for weight loss exploded in popularity, shortages quickly followed. That’s when compounding pharmacies stepped in, offering lower-cost, customizable versions of these medications. But are patients really getting the same...
* Our findings suggest that the presence of OSA risk factors may alter the effect of TRT on OSA incidence, where TRT is associated with lower incidence in people without risk factors and higher incidence in people with risk factors.
INCIDENCE OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS TAKING...
The guest speakers says it all LOL!
The Obesity Society (TOS) convened a panel of leading experts in obesity medicine, pharmacy, and regulatory law on March 19, 2025, to discuss the growing concerns surrounding the use of compounded GLP-1s for weight management and diabetes treatment. The...
I just found out about the whole ban on compounded tirzepatide (I been living under a rock apparently).
My provider presents these options to me now:
Empower Pharmacy (Tirzepatide/Niacinamide)
Strive (Tirzepatide/Glycine/B12)
Southend Pharmacy (Tirzepatide/B6)
Red Rock (Tirzepatide/Glycine)
I...
In this episode, Dr. Rena Malik, MD, and Dr. Alexandra Sowa dive into the transformative effects of new obesity medications, highlighting dramatic weight loss results and their profound impact on personal and romantic relationships. They explore both the psychological and social dimensions...
Johns Hopkins sleep surgeon and airway specialist Kevin Motz will discuss the newest medical and surgical options for patients with obstructive sleep apnea (OSA) who struggle with using a continuous positive airway pressure (CPAP) machine.
In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.
https://www.hcplive.com/view/diabetes-dialogue-exploring-new-horizons-in-incretin-therapy-for-diabetes-and-weight-loss...
SURMOUNT-OSA Results: 'Impressive' in Improving Sleep Apnea
Drs Akshay Jain and James Kim discuss the benefits of GLP-1 therapy for sleep apnea, as reported from the SURMOUNT-OSA trial.
Key Insights from the Surmount OSA Study: Implications for Primary Care and Endocrinology
Introduction
Dr...
Ross Arena, PhD, Professor and Head of the Department of Physical Therapy, College of Applied Health Sciences, at the University of Illinois at Chicago, reviews his article appearing in the December 2024 issue of Mayo Clinic Proceedings, where he finds promise in the newly emerging medical...
Ozempic, Wegovy and Mounjaro are turning out to be some of the most successful drugs ever churned out by pharmaceutical companies. That’s because when it comes to treating type 2 diabetes and causing weight loss, they really do work. Sales are set to soar to even greater heights because...